StockStory.org on MSN
5 must-read analyst questions from PacBio’s Q4 earnings call
Pacific Biosciences’ fourth quarter results exceeded Wall Street’s expectations, supported by record consumables revenue and ...
New SPRQ-Nx chemistry designed to deliver the most complete view of the genome for less than $300 at scale MENLO PARK, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the ...
Now that Pacific Biosciences has broken through the $1 level that avoids Nasdaq delisting for now, we can focus on what might be ahead: the near-term path to cash flow breakeven. PacBio’s biggest ...
Pacific Biosciences of California (NASDAQ:PACB) reported fourth-quarter and full-year 2025 results that management said exceeded expectations, driven by record consumables revenue and stronger ...
Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, delivered an adjusted loss per share of 13 cents in second-quarter 2025, narrower than the year-ago adjusted loss of 20 cents ...
Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued product development. The optimism, led by strong third-quarter results, is expected to ...
MENLO PARK, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced innovations to its Revio and Vega platforms ...
MENLO PARK, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced innovations to its Revio and Vega platforms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results